Ocrelizumab is a recombinant humanized MAb that is designed to selectively target CD20-positive B cells, which are key contributors to myelin and axonal damage that can lead to disability in patients with multiple sclerosis. Ocrelizumab is indicated in adult patients with relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. The goal of ocrelizumab therapy is to reduce inflammatory brain lesions.
Mar. 17, 2021